Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome
Open Access
- 2 March 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1737537
Abstract
Objective: Systematically analyze the global landscape of interventional clinical trials on gut microbiota modulation (GMM) therapies for irritable bowel syndrome (IBS). Methods: Searched the Trialtrove database (1998–July 2025) with the key term combination “(Disease is Autoimmune/Inflammation: Irritable Bowel Syndrome) AND (Mechanism of Action: Microbiome modulator)”, included 305 interventional trials (excluded 15 observational studies). Descriptive analysis was done via SPSS 26.0, adhering to TITAN Guidelines 2025. Results: Asia was the most active region; trials peaked in 2021, with Phase II (44.3%) and IV (33.3%) dominant. Probiotics led (single-strain: Lactobacillus/Bifidobacterium; multi-strain: Lactobacillus + Bifidobacterium), followed by fecal microbiota transplantation (FMT). IBS-D (49.6%) was the main subtype (IBS-C: 26.1%); probiotics were the most frequently studied for both, FMT for IBS-D, and prebiotics for IBS-C. Conclusion: GMM therapies for IBS are relatively mature. Personalized therapies are necessary; multiomics and emerging therapies (e.g., Akkermansia muciniphila ) will promote IBS precision medicine.Keywords
Funding Information
- Youth Program of the Open Fund of the State Key Laboratory of Innovative Drug Research for Neurological and Oncological Disorders (SKLSIM-F-202443)
- Sichuan Medical Association (SC202401)
- Youth Program of the Department of Education (13ZB0243)
- National Natural Science Foundation of China (81702093)
This publication has 12 references indexed in Scilit:
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® modelBMC Complementary Medicine and Therapies, 2025
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitisMicrobiome, 2024
- Effects of a live versus heat-inactivated probiotic Bifidobacterium spp in preterm infants: a randomised clinical trialArchives of Disease in Childhood - Fetal and Neonatal Edition, 2024
- Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-AnalysisNutrients, 2023
- Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary managementNature Reviews Gastroenterology & Hepatology, 2023
- Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and SymptomsNutrients, 2023
- Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2020
- Systematic review and meta‐analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndromeNeurogastroenterology & Motility, 2018
- Letter: what gastroenterologists should know about VSL#3Alimentary Pharmacology & Therapeutics, 2018
- Clinical trial:Lactobacillus plantarum299v (DSM 9843) improves symptoms of irritable bowel syndromeWorld Journal of Gastroenterology, 2012